GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Cash Flow from Operations

LadRx (LADX) Cash Flow from Operations : $1.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, LadRx's Net Income From Continuing Operations was $-0.86 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $-0.01 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $-0.00 Mil. In all, LadRx's Cash Flow from Operations for the three months ended in Dec. 2023 was $-0.86 Mil.


LadRx Cash Flow from Operations Historical Data

The historical data trend for LadRx's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Cash Flow from Operations Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.72 -6.14 -12.31 -4.83 1.01

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.57 -0.70 3.25 -0.67 -0.86

LadRx Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

LadRx's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

LadRx's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LadRx  (OTCPK:LADX) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

LadRx's net income from continuing operations for the three months ended in Dec. 2023 was $-0.86 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

LadRx's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

LadRx's change in working capital for the three months ended in Dec. 2023 was $-0.01 Mil. It means LadRx's working capital declined by $0.01 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

LadRx's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

LadRx's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

LadRx's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

LadRx's stock based compensation for the three months ended in Dec. 2023 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

LadRx's cash flow from others for the three months ended in Dec. 2023 was $-0.00 Mil.


LadRx Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of LadRx's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (LADX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
Executives
Cary J Claiborne director 3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy officer: Chief Executive Officer C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis officer: Pres., Chief Operating Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz officer: Vice President Drug Discovery 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d. officer: Senior VP-Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware officer: Chief Commercial Officer 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla director 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland officer: Sr VP - Drug Development 11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro director 11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049